Search results for "Dorzolamid"

showing 8 items of 8 documents

Innovative Glaukomtherapie

2001

Lokale Karboanhydrasehemmer wurden mit Dorzolamid 1995 in die medikamentose Glaukomtherapie eingefuhrt. Im Jahr 2000 wurde nun ein zweiter topischer Karboanhydrasehemmer auf dem deutschen Markt eingefuhrt: Brinzolamid. Die augeninnendrucksenkende Wirkung beider Medikamente ist vergleichbar bei einem etwas unterschiedlichen Nebenwirkungsprofil. Die Breitenanwendung von Dorzolamid zeigt ein positives Nutzen/Risiko-Verhaltnis. Eine Kombinationstherapie mit lokalen Karboanhydrasehemmern bewirkt zusatzlich zu allen anderen topischen Glaukommedikamenten eine weitere Drucksenkung. Zudem liegen im Tierversuch erste Hinweise vor, dass Dorzolamid druckunabhangig die Durchblutungssituation am hinteren…

GynecologyOphthalmologymedicine.medical_specialtybusiness.industryMedicinebusinessDorzolamidDorzolamidaDer Ophthalmologe
researchProduct

Update on topical carbonic anhydrase inhibitors

2001

Topical carbonic anhydrase inhibitors are a novel addition to the armamentarium of medical glaucoma treatment; dorzolamide has been available since 1995 and brinzolamide since 1998. They lower intraocular pressure by inhibiting carbonic anhydrase, a key enzyme for aqueous humor formation. Intraocular pressure-lowering activity of the substances appears to be the same and is similar to that of most other agents, but it does not reach the activity of the unselective beta-blocker timolol or the prostaglandin latanoprost. On concomitant treatment, additivity is reached with all other topical agents. A possible improvement of blood flow may offer an additional benefit, but its significance for t…

Intraocular pressuregenetic structuresBrinzolamideThiazinesGlaucomaTimololThiophenesPharmacologyEyeAqueous Humorchemistry.chemical_compoundDorzolamideCarbonic anhydrasemedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureCarbonic Anhydraseschemistry.chemical_classificationSulfonamidesDose-Response Relationship Drugbiologybusiness.industryGlaucomaGeneral Medicinemedicine.diseaseeye diseasesOphthalmologyEnzymechemistryProstaglandins F Syntheticbiology.proteinLatanoprostsense organsOphthalmic SolutionsbusinessBlood Flow Velocitymedicine.drugCurrent Opinion in Ophthalmology
researchProduct

Intercurrent factors associated with the development of open-angle glaucoma in The European Glaucoma Prevention Study

2007

Purpose: To evaluate the intercurrent factors for the development of open-angle glaucoma (OAG) in ocular hypertensive patients who were enrolled in the European Glaucoma Prevention Study (EGPS). Design: Randomized, double masked, controlled clinical trial. Methods: setting: Multicenter. study population: A total of 1,077 patients fulfilled a series of inclusion criteria, including intraocular pressure (IOP) 22 to 29 mm Hg, normal and reliable visual fields (VFs) and normal optic disks. intervention: Treatment with dorzolamide or placebo. main outcome measures: Glaucoma-related VF or optic disk changes. Clinical data were collected every six months during a five-year follow-up. Proportional …

Intraocular pressuremedicine.medical_specialtyTime Factorsgenetic structuresOpen angle glaucomaSettore MED/06 - Oncologia MedicaOptic DiskOptic diskOcular hypertensionGlaucomaThiopheneslaw.inventionCorneaDouble-Blind MethodDorzolamideRandomized controlled trialRisk FactorslawOphthalmologyConfidence IntervalsPrevalencemedicineHumansDiureticsglaucoma ocular hypertension intercurrent risk factorsAntihypertensive AgentsIntraocular PressureProportional Hazards ModelsRetrospective StudiesSulfonamidesbusiness.industryHazard ratioRetinal Hemorrhagemedicine.diseaseeye diseasesEuropeOphthalmologyTreatment OutcomeCardiovascular Diseasessense organsbusinessGlaucoma Open-AngleFollow-Up Studiesmedicine.drug
researchProduct

Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolam…

2017

Introduction To demonstrate that preoperative treatment for 28 days with topical dorzolamide/timolol is non-inferior (Δ = 4 mm Hg) to oral acetazolamide and topical dexamethasone (standard therapy) in terms of intraocular pressure (IOP) reduction 3 and 6 months after trabeculectomy in glaucoma patients. Materials and methods Sixty-two eyes undergoing trabeculectomy with mitomycin C were included in this monocentric prospective randomized controlled study. IOP change between baseline and 3 months post-op was defined as the primary efficacy variable. Secondary efficacy variables included the number of 5-fluorouracil (5-FU) injections, needlings, suture lyses, preoperative IOP change, hyperten…

MaleIntraocular pressuregenetic structuresEye DiseasesPhysiologymedicine.medical_treatmentTimololGlaucomalcsh:Medicine030204 cardiovascular system & hematologyDexamethasone0302 clinical medicineGlaucoma surgeryMedicine and Health SciencesMedicineTrabeculectomyProspective Studieslcsh:ScienceSulfonamidesMultidisciplinaryPharmaceuticsDorzolamide/TimololOphthalmic ProceduresMiddle AgedDrug CombinationsTreatment OutcomeResearch DesignAnesthesiaTimololFemaleFluorouracilAnatomyAcetazolamidemedicine.drugResearch Articlemedicine.medical_specialtyLysis (Medicine)Clinical Research DesignSurgical and Invasive Medical ProceduresTrabeculectomyThiophenesResearch and Analysis Methods03 medical and health sciencesMusculoskeletal System ProceduresDorzolamideDrug TherapyOcular SystemOphthalmologyTissue RepairPreoperative CareHumansAntihypertensive AgentsIntraocular PressureAgedbusiness.industrylcsh:RBiology and Life SciencesGlaucomamedicine.diseaseeye diseasesAcetazolamideOphthalmology030221 ophthalmology & optometryEyeslcsh:QOcular Hypertensionsense organsAdverse EventsOphthalmic SolutionsbusinessPhysiological ProcessesHeadPLoS ONE
researchProduct

Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.

2010

To evaluate the efficacy and tolerability of preservative-free eye drops (dorzolamide/timolol) in routine management of preservative-sensitive glaucoma patients.Data from 2,298 glaucoma patients requiring intraocular pressure (IOP) reduction and suffering from intolerance to benzalkonium chloride or active agents of previously used eye drops were valid for baseline and safety analysis in this prospective, open, noncomparative, multicenter, noninterventional study. Patients were treated with preservative-free dorzolamide/timolol eye drops for 12 weeks. Main efficacy endpoint was IOP reduction after 12 weeks of treatment. Two thousand forty-nine patients were considered for efficacy analysis.…

MaleIntraocular pressuregenetic structuresEye diseasemedicine.medical_treatmentAdministration TopicalGlaucomaTimololHyperemiaThiophenesDorzolamideMedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyAntihypertensive AgentsIntraocular PressureAgedPharmacologySulfonamidesbusiness.industryPreservatives PharmaceuticalEye dropmedicine.diseaseeye diseasesOphthalmologyDrug CombinationsTreatment OutcomeTolerabilityAnesthesiaTimololFemalesense organsOphthalmic SolutionsbusinessBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
researchProduct

Carbonic anhydrase inhibitors

1999

Reaction of 20 aromatic/heterocyclic sulfonamides containing a free amino, imino, hydrazino or hydroxyl group, with 8-quinoline-sulfonyl chloride afforded a series of water-soluble (as hydrochloride or triflate salts) compounds. The new derivatives were assayed as inhibitors of the zinc enzyme carbonic anhydrase (CA), and more precisely of three of its isozymes, CA I, II (cytosolic forms) and IV (membrane-bound form), involved in important physiological processes. Efficient inhibition was observed against all three isozymes, but especially against CA II (in nanomolar range), which is the isozyme known to play a critical role in aqueous humor secretion within the ciliary processes of the eye…

chemistry.chemical_classificationSulfonylbiologyChemistryHydrochlorideOrganic ChemistryClinical BiochemistryQuinolinePharmaceutical ScienceBiochemistryMedicinal chemistrySulfonamidechemistry.chemical_compoundDorzolamideEnzyme inhibitorCarbonic anhydraseDrug Discoverybiology.proteinmedicineMolecular MedicineMoietyOrganic chemistryMolecular Biologymedicine.drugBioorganic & Medicinal Chemistry
researchProduct

Prävention des früh-postoperativen IOD-Anstiegs nach Phakoemulsifikation

2001

Purpose. To compare the ocular hypotensive effect of different antiglaucomatous eye drops. Patients and methods. This double-blind, randomized study included 119 eyes of 119 patients without other ocular pathology undergoing standardized (one surgeon, Healon) small incision cataract surgery with foldable intraocular lens implantation.The patients were assigned to one of five groups: group 1:0.25% timolol in Gelrite (extended efficacy, n=23); group 2: 2% dorzolamide (n=24); group 3: combination of 0.5% timolol plus 2% dorzolamide (n=22); group 4: brimonidine (n=26); group 5: gentamicin (control, n=24). Intraocular pressure (IOP) was measured preoperatively and at 3±1,6±1,9±1,24±3, and 48±3 h…

medicine.medical_specialtyIntraocular pressuregenetic structuresbusiness.industrymedicine.medical_treatmentBrimonidineTimololIntraocular lensPhacoemulsificationCataract surgeryeye diseasesOphthalmologyDorzolamideOphthalmologyStatistical significancemedicinebusinessmedicine.drugDer Ophthalmologe
researchProduct

Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa.

2006

medicine.medical_specialtyVisual acuitybusiness.industrymedicine.diseaseOphthalmologyDorzolamideOphthalmologyRetinitis pigmentosamedicineIn patientmedicine.symptombusinessMacular edemamedicine.drug
researchProduct